Business

Mylan said that the company is paying approximately $463 million to Novartis for worldwide rights to TOBI Podhaler tobramycin DPI and TOBI tobramycin inhalation solution. Approximately $240 million of that amount will be paid in 2018. The company said that its acquisition of the products, which are approved in a number of countries for the treatment of P. … [Read more...] about Mylan acquires TOBI products from Novartis

Vectura has announced that revenues from inhaled drugs rose 7.1% in the first half of 2018, with Flutiform revenues up 3.1% compared to the first half of 2017 and up 6.1% compared to the second half of 2017. Total revenue for the six months was up 1.4%. The company also said that results from Phase 2 studies of VR647 nebulized budesonide inhalation suspension … [Read more...] about Vectura inhaled product revenues up more than 7% in first half of 2018

According to Mundipharma, Napp Pharmaceuticals has launched the company's Flutiform fluticasone propionate/formoterol fumarate k-haler breath-activated MDI in the UK. The launch is the first in Europe since Flutiform k-haler was approved for the treatment of asthma in patients aged 12 and older through the decentralized procedure in October 2017. Mundipharma … [Read more...] about Napp Pharmaceuticals launches Mundipharma’s Flutiform k-haler in the UK

Consort Medical subsidiaries Aesica and Bespak will manufacture Opiant Pharmaceuticals' OPNT003 nalmefene nasal spray, the companies said. Earlier this year, Opiant announced that it would develop OPNT003 for the treatment of opioid overdose using the 505(b)(2) pathway, and the company has been awarded a grant worth around $7.4 million by the National Institutes … [Read more...] about Consort Medical to manufacture Opiant’s nalmefene nasal spray

Roivant Sciences has acquired global rights to Patara Pharma's PA101 cromolyn sodium inhalation solution for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), the company said. The inhalation solution, which will now be called RVT-1601, is delivered via the PARI eFlow nebulizer. In 2016, Patara announced positive results from a … [Read more...] about Roivant acquires global rights to Patara’s inhaled cromolyn sodium

United Therapeutics will pay MannKind Corporation $45 million up front and up to $50 million in milestone payments, plus potential double-digit royalties for a worldwide exclusive licensing and collaboration agreement for development and commercialization of a treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH), the companies said. In June … [Read more...] about United Therapeutics and MannKind partner for development of treprostinil DPI for PAH

Glenmark Pharmaceuticals said that it has acquired an exclusive license to market a generic tiotropium bromide dry powder inhaler in Western Europe. The DPI, a generic version of Boehringer Ingelheim's Spiriva Handihaler for the treatment of COPD, is the second inhaler Glenmark has licensed for the European market. In 2015, Glenmark announced that it had entered … [Read more...] about Glenmark licenses tiotropium DPI in Western Europe

Product Quest manufacturing, which recently announced a recall of CVS Health 12 Hour Sinus Relief Nasal Mist oxymetazoline nasal spray due to contamination with Pseudomonas aeruginosa, has now recalled all of the nasal products it manufactured at its Florida facility "out of an abundance of caution." The company provided a 63-page document listing over1,000 … [Read more...] about Product Quest recalls nasal sprays sold at major US retailers

Adherium recently received OTC clearance for its Hailie inhaler monitoring platform in the US, and the company says that it has now launched direct-to-consumer sales through a web site. Hailie includes an inhaler sensor and a smartphone app that allows patients to monitor their own inhaler use, and a new web portal will provide health care providers with access to … [Read more...] about Adherium launches Hailie inhaler sensor in US

Haisco Pharmaceutical Group has acquired Chinese rights to products developed by Pneuma Respiratory in a deal that included a $10 million equity investment in Pneuma, the company said. In addition to the equity investment, Haisco will fund Chinese regulatory filings. In July 2018, Pneuma Respiratory said that it had completed a series A fundraising round that … [Read more...] about Haisco gets rights to distribute Pneuma Respiratory products in China